Philip Scheltens
YOU?
Author Swipe
View article: Associations of lifestyle factors with amyloid pathology in persons without dementia
Associations of lifestyle factors with amyloid pathology in persons without dementia Open
Background The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective The aim of this study was to assess the association of alcohol consumption, smoking behavior, slee…
View article: Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease Open
ClinicalTrials.gov Identifier: NCT05142722.
View article: Cerebrospinal fluid proteomic associations of <i>APOE</i> genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease
Cerebrospinal fluid proteomic associations of <i>APOE</i> genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease Open
BACKGROUND The apolipoprotein E ( APOE ) gene includes the strongest protective (ε2) and risk (ε4) variants for sporadic Alzheimer's disease (AD), but underlying mechanisms remain unclear. We studied APOE genotype effects on the cerebrospi…
View article: Neurodevelopment and neural environment inform Alzheimer's disease age at onset and phenotype
Neurodevelopment and neural environment inform Alzheimer's disease age at onset and phenotype Open
INTRODUCTION Risk factors associated with sporadic non‐amnestic and early‐onset Alzheimer's disease (AD) remain underexamined. METHODS We investigated a large, clinically heterogeneous, AD cohort for frequencies of established risk factors…
View article: Connectome-guided personalization of optimal tDCS intervention selection in Alzheimer’s disease
Connectome-guided personalization of optimal tDCS intervention selection in Alzheimer’s disease Open
Transcranial direct current stimulation (tDCS) is being investigated as a clinical intervention in Alzheimer’s disease (AD) with the goal of reducing its neurophysiological effects (i.e. oscillatory slowing and loss of functional connectiv…
View article: Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review
Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review Open
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, predominantly affecting the aging population. Early detection through biomarkers is essential for early intervention. Recent sub‐classification of AD through extens…
View article: Monitoring of amyloid related imaging abnormalities: SWI vs T2*-GRE
Monitoring of amyloid related imaging abnormalities: SWI vs T2*-GRE Open
Amyloid-β-directed monoclonal antibody therapies may lead to amyloid-related imaging abnormalities (ARIA). Clinical trials that formed the basis for the ARIA radiographic severity grading scale adopted by the approved drugs' labels utilize…
View article: Utility, Costs and Cost‐Utility of Amyloid‐<scp>PET</scp> in the Diagnostic Process of Memory Clinic Patients: A Trial‐Based Economic Evaluation From <scp>AMYPAD</scp>‐<scp>DPMS</scp>
Utility, Costs and Cost‐Utility of Amyloid‐<span>PET</span> in the Diagnostic Process of Memory Clinic Patients: A Trial‐Based Economic Evaluation From <span>AMYPAD</span>‐<span>DPMS</span> Open
Background Amyloid positron emission tomography (PET) is instrumental in achieving an accurate diagnosis and may help to limit health‐seeking behavior. Currently, amyloid‐PET is not routinely used in clinical practice due to lack of eviden…
View article: Characterizing visual read tau‐PET‐negative participants with Alzheimer's disease dementia
Characterizing visual read tau‐PET‐negative participants with Alzheimer's disease dementia Open
INTRODUCTION A subset of amyloid beta (Aβ)‐positive Alzheimer's disease (AD) patients is tau‐positron emission tomography (PET) negative. We aimed to characterize this subgroup using [ 18 F]flortaucipir PET visual read (VR), as this is imp…
View article: evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease Open
Clinicaltrials.gov, NCT04777396 and NCT04777409. Date: 02/03/2021.
View article: Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure
Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure Open
Cavum septum pellucidum (CSP) is commonly observed upon neuroimaging examination in individuals exposed to repetitive head impacts (RHI) and post-mortem in cases with chronic traumatic encephalopathy. Consequently, CSP has been proposed as…
View article: Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy
Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy Open
Limbic predominant age‐related TDP‐43 encephalopathy neuropathologic change (LATE‐NC) is highly prevalent in late life and a common co‐pathology with Alzheimer's disease neuropathologic change (ADNC). LATE‐NC is a slowly progressive, amnes…
View article: evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease Open
Background: Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer’s disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist sema…
View article: Cavum Septum Pellucidum (CSP) as a Neuroimaging Signature of Head Impact Exposure compared to Non‐exposed Patients with Neurodegenerative Disease and Controls
Cavum Septum Pellucidum (CSP) as a Neuroimaging Signature of Head Impact Exposure compared to Non‐exposed Patients with Neurodegenerative Disease and Controls Open
Background Cavum Septum Pellucidum [CSP] is commonly observed on neuroimaging in individuals exposed to repetitive head impacts [RHI] and in post‐mortem examination in Chronic Traumatic Encephalopathy [CTE]. A CSP is proposed as a potentia…
View article: Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD
Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD Open
Background Alzheimer’s disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility c…
View article: Image‐derived phenotypes in the AMYPAD Prognostic and Natural History Study
Image‐derived phenotypes in the AMYPAD Prognostic and Natural History Study Open
Background The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic & Natural History Study (PNHS) is a prospective longitudinal PET cohort of over 1,500 non‐demented individuals from 10 parent cohorts across Europe. We provi…
View article: Cavum Septum Pellucidum (CSP) as a Neuroimaging Signature of Head Impact Exposure compared to Non‐exposed Patients with Neurodegenerative Disease and Controls
Cavum Septum Pellucidum (CSP) as a Neuroimaging Signature of Head Impact Exposure compared to Non‐exposed Patients with Neurodegenerative Disease and Controls Open
Background Cavum Septum Pellucidum [CSP] is commonly observed on neuroimaging in individuals exposed to repetitive head impacts [RHI] and in post‐mortem examination in Chronic Traumatic Encephalopathy [CTE]. A CSP is proposed as a potentia…
View article: Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease
Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease Open
Background Differences in patient characteristics across geographical regions may result in heterogeneity in clinical trial populations. evoke (NCT04777396) and evoke+ (NCT04777409) are two phase 3, multinational, randomised trials investi…
View article: Image‐derived phenotypes in the AMYPAD Prognostic and Natural History Study
Image‐derived phenotypes in the AMYPAD Prognostic and Natural History Study Open
Background The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic & Natural History Study (PNHS) is a prospective longitudinal PET cohort of over 1,500 non‐demented individuals from 10 parent cohorts across Europe. We provi…
View article: Functional Connectivity and Longitudinal Changes in Amyloid Pathology in Cognitively Healthy Older Adults
Functional Connectivity and Longitudinal Changes in Amyloid Pathology in Cognitively Healthy Older Adults Open
Background Accumulation of amyloid beta in the brain is one of the first events in Alzheimer’s disease (AD) and starts decades before symptoms arise. It has been hypothesized that brain areas with higher levels of neuronal activation (‘hub…